skip to main content
Language:
Search Limited to: Search Limited to: Resource type Show Results with: Show Results with: Search type Index

Results 1 - 20 of 3,176  for All Library Resources

Sorted by: Sorted by: RelevanceOr hit Enter to replace sort method
Results 1 2 3 4 5 next page
Show only
Refined by: language: Russian remove top level: Digital Resources/Online E-Resources remove
Result Number Material Type Add to My Shelf Action Record Details and Options
1
Adverse childhood experiences and associations with health-harming behaviours in young adults: surveys in eight eastern European countries
Adverse childhood experiences and associations with health-harming behaviours in young adults: surveys in eight eastern European countries
Material Type:
Article 		Add to My Research

Adverse childhood experiences and associations with health-harming behaviours in young adults: surveys in eight eastern European countries

Bulletin of the World Health Organization, 2014-09, Vol.92 (9), p.641-655 [Peer Reviewed Journal]

2015 INIST-CNRS ;Copyright World Health Organization Sep 2014 ;(c) 2014 The authors; licensee World Health Organization. 2014 ;ISSN: 0042-9686 ;EISSN: 1564-0604 ;DOI: 10.2471/BLT.13.129247 ;PMID: 25378755 ;CODEN: BWHOA6

Full text available

Citations Cited by
2
Prevalence of and risk factors for resistance to second-line drugs in people with multidrug-resistant tuberculosis in eight countries: a prospective cohort study
Prevalence of and risk factors for resistance to second-line drugs in people with multidrug-resistant tuberculosis in eight countries: a prospective cohort study
Material Type:
Article 		Add to My Research

Prevalence of and risk factors for resistance to second-line drugs in people with multidrug-resistant tuberculosis in eight countries: a prospective cohort study

The Lancet (British edition), 2012-10, Vol.380 (9851), p.1406-1417 [Peer Reviewed Journal]

Elsevier Ltd ;2012 Elsevier Ltd ;2015 INIST-CNRS ;Copyright © 2012 Elsevier Ltd. All rights reserved. ;ISSN: 0140-6736 ;EISSN: 1474-547X ;DOI: 10.1016/S0140-6736(12)60734-X ;PMID: 22938757 ;CODEN: LANCAO

Full text available

Citations Cited by
3
Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial
Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial
Material Type:
Article 		Add to My Research

Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial

The Lancet (British edition), 2014-01, Vol.383 (9911), p.31-39 [Peer Reviewed Journal]

Elsevier Ltd ;2014 Elsevier Ltd ;2015 INIST-CNRS ;Copyright © 2014 Elsevier Ltd. All rights reserved. ;Copyright Elsevier Limited Jan 4, 2014 ;ISSN: 0140-6736 ;EISSN: 1474-547X ;DOI: 10.1016/S0140-6736(13)61719-5 ;PMID: 24094768 ;CODEN: LANCAO

Full text available

Citations Cited by
4
Addition of Aflibercept to Fluorouracil, Leucovorin, and Irinotecan Improves Survival in a Phase III Randomized Trial in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin-Based Regimen
Addition of Aflibercept to Fluorouracil, Leucovorin, and Irinotecan Improves Survival in a Phase III Randomized Trial in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin-Based Regimen
Material Type:
Article 		Add to My Research

Addition of Aflibercept to Fluorouracil, Leucovorin, and Irinotecan Improves Survival in a Phase III Randomized Trial in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin-Based Regimen

Journal of clinical oncology, 2012-10, Vol.30 (28), p.3499-3506 [Peer Reviewed Journal]

2015 INIST-CNRS ;ISSN: 0732-183X ;EISSN: 1527-7755 ;DOI: 10.1200/JCO.2012.42.8201 ;PMID: 22949147

Full text available

Citations Cited by
5
Brivanib Versus Sorafenib As First-Line Therapy in Patients With Unresectable, Advanced Hepatocellular Carcinoma: Results From the Randomized Phase III BRISK-FL Study
Brivanib Versus Sorafenib As First-Line Therapy in Patients With Unresectable, Advanced Hepatocellular Carcinoma: Results From the Randomized Phase III BRISK-FL Study
Material Type:
Article 		Add to My Research

Brivanib Versus Sorafenib As First-Line Therapy in Patients With Unresectable, Advanced Hepatocellular Carcinoma: Results From the Randomized Phase III BRISK-FL Study

Journal of clinical oncology, 2013-10, Vol.31 (28), p.3517-3524 [Peer Reviewed Journal]

2014 INIST-CNRS ;ISSN: 0732-183X ;EISSN: 1527-7755 ;DOI: 10.1200/JCO.2012.48.4410 ;PMID: 23980084

Full text available

Citations Cited by
6
Randomized Phase III Trial of Maintenance Bevacizumab With or Without Pemetrexed After First-Line Induction With Bevacizumab, Cisplatin, and Pemetrexed in Advanced Nonsquamous Non–Small-Cell Lung Cancer: AVAPERL (MO22089)
Randomized Phase III Trial of Maintenance Bevacizumab With or Without Pemetrexed After First-Line Induction With Bevacizumab, Cisplatin, and Pemetrexed in Advanced Nonsquamous Non–Small-Cell Lung Cancer: AVAPERL (MO22089)
Material Type:
Article 		Add to My Research

Randomized Phase III Trial of Maintenance Bevacizumab With or Without Pemetrexed After First-Line Induction With Bevacizumab, Cisplatin, and Pemetrexed in Advanced Nonsquamous Non–Small-Cell Lung Cancer: AVAPERL (MO22089)

Journal of clinical oncology, 2013-08, Vol.31 (24), p.3004-3011 [Peer Reviewed Journal]

2014 INIST-CNRS ;ISSN: 0732-183X ;ISSN: 1527-7755 ;EISSN: 1527-7755 ;DOI: 10.1200/JCO.2012.42.3749 ;PMID: 23835708

Full text available

Citations Cited by
7
Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial
Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial
Material Type:
Article 		Add to My Research

Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial

The Lancet (British edition), 2013-01, Vol.381 (9861), p.125-132 [Peer Reviewed Journal]

Elsevier Ltd ;2013 Elsevier Ltd ;2014 INIST-CNRS ;Copyright © 2013 Elsevier Ltd. All rights reserved. ;Copyright Elsevier Limited Jan 12, 2013 ;ISSN: 0140-6736 ;EISSN: 1474-547X ;DOI: 10.1016/S0140-6736(12)61134-9 ;PMID: 23158522 ;CODEN: LANCAO

Full text available

Citations Cited by
8
RIBBON-1: Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of Chemotherapy With or Without Bevacizumab for First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative, Locally Recurrent or Metastatic Breast Cancer
RIBBON-1: Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of Chemotherapy With or Without Bevacizumab for First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative, Locally Recurrent or Metastatic Breast Cancer
Material Type:
Article 		Add to My Research

RIBBON-1: Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of Chemotherapy With or Without Bevacizumab for First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative, Locally Recurrent or Metastatic Breast Cancer

Journal of clinical oncology, 2011-04, Vol.29 (10), p.1252-1260 [Peer Reviewed Journal]

2015 INIST-CNRS ;ISSN: 0732-183X ;EISSN: 1527-7755 ;DOI: 10.1200/JCO.2010.28.0982 ;PMID: 21383283

Full text available

Citations Cited by
9
Cigarette smoking and lung cancer—relative risk estimates for the major histological types from a pooled analysis of case–control studies
Cigarette smoking and lung cancer—relative risk estimates for the major histological types from a pooled analysis of case–control studies
Material Type:
Article 		Add to My Research

Cigarette smoking and lung cancer—relative risk estimates for the major histological types from a pooled analysis of case–control studies

International journal of cancer, 2012-09, Vol.131 (5), p.1210-1219 [Peer Reviewed Journal]

ISSN: 1097-0215 ;EISSN: 1097-0215 ;DOI: 10.1002/ijc.27339

Digital Resources/Online E-Resources

Citations Cited by
10
Cigarette, Cigar, and Pipe Smoking and the Risk of Head and Neck Cancers: Pooled Analysis in the International Head and Neck Cancer Epidemiology Consortium
Cigarette, Cigar, and Pipe Smoking and the Risk of Head and Neck Cancers: Pooled Analysis in the International Head and Neck Cancer Epidemiology Consortium
Material Type:
Article 		Add to My Research

Cigarette, Cigar, and Pipe Smoking and the Risk of Head and Neck Cancers: Pooled Analysis in the International Head and Neck Cancer Epidemiology Consortium

American journal of epidemiology, 2013-09, Vol.178 (5), p.679-690 [Peer Reviewed Journal]

2014 INIST-CNRS ;Copyright Oxford Publishing Limited(England) Sep 1, 2013 ;The Author 2013. Published by Oxford University Press on behalf of the Johns Hopkins Bloomberg School of Public Health. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com. 2013 ;ISSN: 0002-9262 ;EISSN: 1476-6256 ;DOI: 10.1093/aje/kwt029 ;PMID: 23817919 ;CODEN: AJEPAS

Full text available

Citations Cited by
11
Multicenter Phase III Comparison of Cisplatin/S-1 With Cisplatin/Infusional Fluorouracil in Advanced Gastric or Gastroesophageal Adenocarcinoma Study: The FLAGS Trial
Multicenter Phase III Comparison of Cisplatin/S-1 With Cisplatin/Infusional Fluorouracil in Advanced Gastric or Gastroesophageal Adenocarcinoma Study: The FLAGS Trial
Material Type:
Article 		Add to My Research

Multicenter Phase III Comparison of Cisplatin/S-1 With Cisplatin/Infusional Fluorouracil in Advanced Gastric or Gastroesophageal Adenocarcinoma Study: The FLAGS Trial

Journal of clinical oncology, 2010-03, Vol.28 (9), p.1547-1553 [Peer Reviewed Journal]

2015 INIST-CNRS ;ISSN: 0732-183X ;EISSN: 1527-7755 ;DOI: 10.1200/JCO.2009.25.4706 ;PMID: 20159816

Full text available

Citations Cited by
12
Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome–positive chronic myeloid leukemia patients with resistance or intolerance to imatinib
Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome–positive chronic myeloid leukemia patients with resistance or intolerance to imatinib
Material Type:
Article 		Add to My Research

Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome–positive chronic myeloid leukemia patients with resistance or intolerance to imatinib

Blood, 2011-10, Vol.118 (17), p.4567-4576 [Peer Reviewed Journal]

2011 American Society of Hematology ;2015 INIST-CNRS ;2011 by The American Society of Hematology 2011 ;ISSN: 0006-4971 ;EISSN: 1528-0020 ;DOI: 10.1182/blood-2011-05-355594 ;PMID: 21865346

Full text available

Citations Cited by
13
Once daily dolutegravir (S/GSK1349572) in combination therapy in antiretroviral-naive adults with HIV: planned interim 48 week results from SPRING-1, a dose-ranging, randomised, phase 2b trial
Once daily dolutegravir (S/GSK1349572) in combination therapy in antiretroviral-naive adults with HIV: planned interim 48 week results from SPRING-1, a dose-ranging, randomised, phase 2b trial
Material Type:
Article 		Add to My Research

Once daily dolutegravir (S/GSK1349572) in combination therapy in antiretroviral-naive adults with HIV: planned interim 48 week results from SPRING-1, a dose-ranging, randomised, phase 2b trial

The Lancet infectious diseases, 2012-02, Vol.12 (2), p.111-118 [Peer Reviewed Journal]

Elsevier Ltd ;2012 Elsevier Ltd ;2015 INIST-CNRS ;Copyright © 2012 Elsevier Ltd. All rights reserved. ;Copyright Elsevier Limited Feb 2012 ;ISSN: 1473-3099 ;EISSN: 1474-4457 ;DOI: 10.1016/S1473-3099(11)70290-0 ;PMID: 22018760 ;CODEN: LANCAO

Full text available

Citations Cited by
14
Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure
Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure
Material Type:
Article 		Add to My Research

Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure

Blood, 2012-04, Vol.119 (15), p.3403-3412 [Peer Reviewed Journal]

2012 American Society of Hematology ;2015 INIST-CNRS ;2012 by The American Society of Hematology 2012 ;ISSN: 0006-4971 ;EISSN: 1528-0020 ;DOI: 10.1182/blood-2011-11-390120 ;PMID: 22371878

Full text available

Citations Cited by
15
Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: a randomised, double-blind, placebo-controlled trial
Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: a randomised, double-blind, placebo-controlled trial
Material Type:
Article 		Add to My Research

Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: a randomised, double-blind, placebo-controlled trial

The Lancet (British edition), 2009-02, Vol.373 (9664), p.641-648 [Peer Reviewed Journal]

Elsevier Ltd ;2009 Elsevier Ltd ;2009 INIST-CNRS ;Copyright Elsevier Limited Feb 21-Feb 27, 2009 ;ISSN: 0140-6736 ;EISSN: 1474-547X ;DOI: 10.1016/S0140-6736(09)60402-5 ;PMID: 19231632 ;CODEN: LANCAO

Full text available

Citations Cited by
16
Higher Education for Adults in Russia: Barriers and Models
Higher Education for Adults in Russia: Barriers and Models
Material Type:
Article 		Add to My Research

Higher Education for Adults in Russia: Barriers and Models

Sotsiologicheskie issledovaniia, 2022 (2), p.34 [Peer Reviewed Journal]

Copyright Russian Academy of Sciences, c/o Izdatelstvo Nauka 2022 ;ISSN: 0132-1625 ;DOI: 10.31857/S013216250016092-4

Full text available

Citations Cited by
17
A randomized, double-blind, placebo-controlled study of the CRTH2 antagonist OC000459 in moderate persistent asthma
A randomized, double-blind, placebo-controlled study of the CRTH2 antagonist OC000459 in moderate persistent asthma
Material Type:
Article 		Add to My Research

A randomized, double-blind, placebo-controlled study of the CRTH2 antagonist OC000459 in moderate persistent asthma

Clinical and experimental allergy, 2012-01, Vol.42 (1), p.38-48 [Peer Reviewed Journal]

2011 Blackwell Publishing Ltd ;2015 INIST-CNRS ;2011 Blackwell Publishing Ltd. ;Copyright © 2012 Blackwell Publishing Ltd ;ISSN: 0954-7894 ;EISSN: 1365-2222 ;DOI: 10.1111/j.1365-2222.2011.03813.x ;PMID: 21762224

Full text available

Citations Cited by
18
Randomized Phase Ib/II Trial of Rilotumumab or Ganitumab with Panitumumab versus Panitumumab Alone in Patients with Wild-type KRAS Metastatic Colorectal Cancer
Randomized Phase Ib/II Trial of Rilotumumab or Ganitumab with Panitumumab versus Panitumumab Alone in Patients with Wild-type KRAS Metastatic Colorectal Cancer
Material Type:
Article 		Add to My Research

Randomized Phase Ib/II Trial of Rilotumumab or Ganitumab with Panitumumab versus Panitumumab Alone in Patients with Wild-type KRAS Metastatic Colorectal Cancer

Clinical cancer research, 2014-08, Vol.20 (16), p.4240-4250 [Peer Reviewed Journal]

2015 INIST-CNRS ;2014 American Association for Cancer Research. ;2014 American Association for Cancer Research. 2014 ;ISSN: 1078-0432 ;EISSN: 1557-3265 ;DOI: 10.1158/1078-0432.CCR-13-2752 ;PMID: 24919569 ;CODEN: CCREF4

Full text available

Citations Cited by
19
Ambulatory Hypertension Subtypes and 24-Hour Systolic and Diastolic Blood Pressure as Distinct Outcome Predictors in 8341 Untreated People Recruited From 12 Populations
Ambulatory Hypertension Subtypes and 24-Hour Systolic and Diastolic Blood Pressure as Distinct Outcome Predictors in 8341 Untreated People Recruited From 12 Populations
Material Type:
Article 		Add to My Research

Ambulatory Hypertension Subtypes and 24-Hour Systolic and Diastolic Blood Pressure as Distinct Outcome Predictors in 8341 Untreated People Recruited From 12 Populations

Circulation (New York, N.Y.), 2014-08, Vol.130 (6), p.466-474 [Peer Reviewed Journal]

2014 by the American College of Cardiology Foundation and the American Heart Association, Inc. ;2015 INIST-CNRS ;2014 American Heart Association, Inc. ;2014 American Heart Association, Inc. 2014 ;ISSN: 0009-7322 ;ISSN: 1524-4539 ;EISSN: 1524-4539 ;DOI: 10.1161/CIRCULATIONAHA.113.004876 ;PMID: 24906822 ;CODEN: CIRCAZ

Full text available

Citations Cited by
20
Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial
Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial
Material Type:
Article 		Add to My Research

Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial

The Lancet (British edition), 2013-03, Vol.381 (9869), p.817-824 [Peer Reviewed Journal]

Elsevier Ltd ;2014 INIST-CNRS ;Copyright Elsevier Limited Mar 9, 2013 ;ISSN: 0140-6736 ;EISSN: 1474-547X ;DOI: 10.1016/S0140-6736(12)61767-X ;PMID: 23312829 ;CODEN: LANCAO

Full text available

Citations Cited by

Results 1 - 20 of 3,176  for All Library Resources

Sorted by: Sorted by: RelevanceOr hit Enter to replace sort method
Results 1 2 3 4 5 next page

Personalize your results

  1. Edit

Refine Search Results

Expand My Results

  1.   

Show only

  1. Peer-reviewed Journals (3,111)

Refine My Results

Creation Date 

From To
Refine
  1. Before 1978  (19)
  2. 1978 To 1996  (49)
  3. 1997 To 2004  (172)
  4. 2005 To 2013  (1,665)
  5. After 2013  (1,273)
  6. More options open sub menu

Resource Type 

  1. Articles  (3,164)
  2. Web Resources  (7)
  3. magazinearticle  (3)
  4. Books  (2)
  5. More options open sub menu

Language 

  1. English  (1,284)
  2. Japanese  (89)
  3. German  (17)
  4. Serbian  (9)
  5. French  (7)
  6. Ukrainian  (7)
  7. Georgian  (2)
  8. Portuguese  (1)
  9. Spanish  (1)
  10. More options open sub menu

on this subject:

  1. Humans
  2. Adult
  3. Female
  4. Male
  5. Middle Aged
INSPIRE LIBRARY - TON DUC THANG UNIVERSITY (84-028) 37 755 057 Feedback
19 Nguyen Huu Tho St. Dist.7, HCM thuvien@tdtu.edu.vn

Copyright © 2017 INSPIRE LIBRARY - TON DUC THANG UNIVERSITY

Searching Remote Databases, Please Wait